SAN DIEGO, March 13, 2019 /PRNewswire/ -- Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor ...
BEAVERTON, Ore., Sept. 16, 2021 /PRNewswire/ -- Tektronix, Inc., a leading worldwide provider of test and measurement solutions, today released KTE V7.1 software for the Keithley S530 Series ...
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers In all, 142 (95%) of 150 questionnaires were completed by 38 ...
In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen ...
SAN DIEGO (KGTV) -- As an active 45-year-old man who loves to surf and take adventures with his daughter, Bryce Olson was the last person his friends expected to get cancer. In 2014, a call while at ...
Qiagen N.V. has announced that it is commercializing the research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to ...
* Qiagen NV - Qiagen has acquired an exclusive worldwide license from Johns Hopkins University Source text for Eikon: Further company coverage: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback